

Table S1. Clinical and morphological parameters of the patients included in the study.

| Patients# | Age | Histological Type and Grade | Estrogen Receptor Status | Progesterone Receptor Status | HER2 Receptor Status | Lymph Node Metastasis Status | Ki67, % | MFS¹, month |
|------------------|------------|---|---------------------------------|-------------------------------------|-----------------------------|-------------------------------------|----------------|-------------------------------|
| Patient#1 | 59 | Invasive carcinoma grade 2, Stage: T2N1M0 | 8 | Negative | 1+ | Negative | 45 | 6 |
| Patient#2 | 54 | Invasive carcinoma grade 1, Stage: T1NxM0 | 7 | 5 | 1+ | Negative | 32 | 12 |
| Patient#3 | 39 | Invasive ductal carcinoma grade 2, Stage: T2N2M0 | 7b | Positive | Negative | Negative | 35 | 2 |
| Patient#4 | 42 | Invasive carcinoma grade 2, Stage: T2N1M0 | Negative | Negative | Negative | Positive | 65 | 20 |
| Patient#5 | 63 | Invasive lobar duct cancer with DCIS comedie type foci, a multicentric form of tumor growth. grade 2, Stage: T2N2M0 | 8 | 4 | Negative | Positive | 42 | 12 |
| Patient#6 | 57 | Invasive carcinoma, grade 2, Stage: T2N0M0 | 8b | 4b | 3+ | Negative | 37 | 5 |
| Patient#7 | 49 | Invasive carcinoma, grade 2, Stage: T2NxMx | Negative | Negative | Negative | Negative | 38 | 24 |
| Patient#8 | 60 | Invasive carcinoma, grade Luminal B, Stage: T2N1Mx | Negative | Negative | Negative | Negative | 45 | 12 |

| | | | | | | | | |
|------------|----|--|----------|----------|----------|----------|----|----|
| Patient#9 | 38 | Invasive carcinoma grade 2, Stage: T2N1M0 | Negative | Negative | Negative | Negative | 41 | 20 |
| Patient#10 | 42 | Invasive carcinoma grade 2, Luminal B, Stage: T2N0M0 | Negative | Negative | Negative | Positive | 62 | 10 |
| Patient#11 | 66 | Invasive carcinoma grade 2, Stage: T3N2M0 | 7 | Negative | 1+ | Negative | 35 | 24 |
| Patient#12 | 38 | Invasive carcinoma grade 2, Stage: T2N1M0 | 8 | Positive | Negative | Negative | 44 | 24 |

Abbreviations: ¹MFS, metastasis-free survival.